

Amir M Sherif

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4155634/publications.pdf>

Version: 2024-02-01

80
papers

3,796
citations

257450

24
h-index

128289

60
g-index

83
all docs

83
docs citations

83
times ranked

4298
citing authors

#	ARTICLE	IF	CITATIONS
1	Bladder cancer recurrence in papillary urothelial neoplasm of low malignant potential (PUNLMP) compared to G1 WHO 1999: a population-based study. <i>Scandinavian Journal of Urology</i> , 2022, 56, 14-18.	1.0	4
2	A prospective multicenter study of visual response-evaluation by cystoscopy in patients undergoing neoadjuvant chemotherapy for muscle invasive urinary bladder cancer. <i>Scandinavian Journal of Urology</i> , 2022, 56, 20-26.	1.0	2
3	Risk of bladder cancer death in patients younger than 50 with non-muscle-invasive and muscle-invasive bladder cancer. <i>Scandinavian Journal of Urology</i> , 2022, 56, 27-33.	1.0	5
4	Nomograms including the UBC Rapid test to detect primary bladder cancer based on a multicentre dataset. <i>BJU International</i> , 2022, 130, 754-763.	2.5	6
5	Swedish National Guidelines on Urothelial Carcinoma: 2021 update on non-muscle invasive bladder cancer and upper tract urothelial carcinoma. <i>Scandinavian Journal of Urology</i> , 2022, 56, 137-146.	1.0	8
6	Standardized care pathways for patients with suspected urinary bladder cancer: the Swedish experience. <i>Scandinavian Journal of Urology</i> , 2022, 56, 227-232.	1.0	5
7	Do not throw out the baby with the bath water. <i>Scandinavian Journal of Urology</i> , 2022, 56, 235-236.	1.0	0
8	The intratumoral CXCR3 chemokine system is predictive of chemotherapy response in human bladder cancer. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	35
9	Cumulative incidence of midline incisional hernia and its surgical treatment after radical cystectomy and urinary diversion for bladder cancer: A nation-wide population-based study. <i>PLoS ONE</i> , 2021, 16, e0246703.	2.5	2
10	A population-based study on the effect of a routine second-look resection on survival in primary stage T1 bladder cancer. <i>Scandinavian Journal of Urology</i> , 2021, 55, 108-115.	1.0	6
11	Thromboembolism in Muscle-Invasive Bladder Cancer. A Population-based Nationwide Study. <i>Bladder Cancer</i> , 2021, 7, 161-171.	0.4	1
12	Survival after radical cystectomy during holiday periods. <i>Scandinavian Journal of Urology</i> , 2021, 55, 276-280.	1.0	2
13	Proteomic Profiling of Tissue Exosomes Indicates Continuous Release of Malignant Exosomes in Urinary Bladder Cancer Patients, Even with Pathologically Undetectable Tumour. <i>Cancers</i> , 2021, 13, 3242.	3.7	10
14	Cumulative incidence of ureteroenteric strictures after radical cystectomy in a population-based Swedish cohort. <i>Scandinavian Journal of Urology</i> , 2021, 55, 361-365.	1.0	8
15	Control computerized tomography in neoadjuvant chemotherapy for muscle invasive urinary bladder cancer has no value for treatment decisions and low correlation with nodal status. <i>Scandinavian Journal of Urology</i> , 2021, 55, 455-460.	1.0	5
16	Immune responses against autologous tumor and human papilloma virus in lymph nodes from patients with penile cancer. <i>Investigative and Clinical Urology</i> , 2021, 62, 39.	2.0	1
17	No increased risk of short-term complications after radical cystectomy for muscle-invasive bladder cancer among patients treated with preoperative chemotherapy: a nation-wide register-based study. <i>World Journal of Urology</i> , 2020, 38, 381-388.	2.2	17
18	Tumour-associated B cells in urothelial urinary bladder cancer. <i>Scandinavian Journal of Immunology</i> , 2020, 91, e12830.	2.7	25

#	ARTICLE	IF	CITATIONS
19	The increased risk for thromboembolism pre-cystectomy in patients undergoing neoadjuvant chemotherapy for muscle-invasive urinary bladder cancer is mainly due to central venous access: a multicenter evaluation. <i>International Urology and Nephrology</i> , 2020, 52, 661-669.	1.4	9
20	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer – An International Collaborative Multistakeholder Effort. <i>European Urology</i> , 2020, 77, 223-250.	1.9	132
21	Fewer tumour draining sentinel nodes in patients with progressing muscle invasive bladder cancer, after neoadjuvant chemotherapy and radical cystectomy. <i>World Journal of Urology</i> , 2020, 38, 2207-2213.	2.2	4
22	Treatment and prognosis of patients with urinary bladder cancer with other primary cancers: a nationwide population-based study in the Bladder Cancer Data Base Sweden (BladderBaSe). <i>BJU International</i> , 2020, 126, 625-632.	2.5	3
23	Computerized tomography before the final treatment cycle of neoadjuvant chemotherapy or induction chemotherapy in muscle-invasive urinary bladder cancer, cannot predict pathoanatomical outcomes and does not reflect prognosis – results of a single centre retrospective prognostic study. <i>Translational Andrology and Urology</i> , 2020, 9, 1062-1072.	1.4	3
24	IL-16 processing in sentinel node regulatory T cells is a factor in bladder cancer immunity. <i>Scandinavian Journal of Immunology</i> , 2020, 92, e12926.	2.7	5
25	Urinary Exosomes from Bladder Cancer Patients Show a Residual Cancer Phenotype despite Complete Pathological Downstaging. <i>Scientific Reports</i> , 2020, 10, 5960.	3.3	35
26	Blood transfusions during neoadjuvant chemotherapy for muscle-invasive urinary bladder cancer may have a negative impact on overall survival. <i>Scandinavian Journal of Urology</i> , 2020, 54, 46-51.	1.0	3
27	Sustainable long-term results on postoperative sexual activity after radical prostatectomy when a clinical sexologist is included in the sexual rehabilitation process. A retrospective study on 7 years postoperative outcome. <i>Central European Journal of Urology</i> , 2020, 73, 551-557.	0.3	1
28	Incidence, survival and mortality trends of bladder cancer in Sweden 1997–2016. <i>Scandinavian Journal of Urology</i> , 2019, 53, 193-199.	1.0	15
29	The risk of oversimplification in risk-stratification of neoadjuvant chemotherapy-responses in muscle invasive bladder cancer. <i>Translational Andrology and Urology</i> , 2019, 8, S337-S340.	1.4	1
30	Management and outcome of muscle-invasive bladder cancer with clinical lymph node metastases. A nationwide population-based study in the bladder cancer data base Sweden (BladderBaSe). <i>Scandinavian Journal of Urology</i> , 2019, 53, 332-338.	1.0	7
31	Management and outcome of TaG3 tumours of the urinary bladder in the nationwide, population-based bladder cancer database Sweden (BladderBaSe). <i>Scandinavian Journal of Urology</i> , 2019, 53, 200-205.	1.0	0
32	Neoadjuvant chemotherapy for muscle invasive bladder cancer: a nationwide investigation on survival. <i>Scandinavian Journal of Urology</i> , 2019, 53, 206-212.	1.0	8
33	Period-specific mean annual hospital volume of radical cystectomy is associated with outcome and perioperative quality of care: a nationwide population-based study. <i>BJU International</i> , 2019, 124, 449-456.	2.5	10
34	EAU – ESMO consensus statements on the management of advanced and variant bladder cancer – an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees. <i>Annals of Oncology</i> , 2019, 30, 1697-1727.	1.2	96
35	Treatment according to guidelines may bridge the gender gap in outcome for patients with stage T1 urinary bladder cancer. <i>Scandinavian Journal of Urology</i> , 2018, 52, 186-193.	1.0	9
36	Urinary Bladder Cancer Tregs Suppress MMP2 and Potentially Regulate Invasiveness. <i>Cancer Immunology Research</i> , 2018, 6, 528-538.	3.4	45

#	ARTICLE	IF	CITATIONS
37	Immune Responses to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2018, 4, 1-7.	0.4	6
38	The long perspective in emergence of neoadjuvant chemotherapy for bladder cancer in Ontario, Canada—space for improvement with regular and organized multidisciplinary team meetings. <i>Translational Andrology and Urology</i> , 2018, 7, 508-510.	1.4	4
39	Detection of micro-metastases by flow cytometry in lymph nodes from patients with penile cancer. <i>BMC Urology</i> , 2018, 18, 86.	1.4	2
40	Urothelial bladder cancer may suppress perforin expression in CD8+ T cells by an ICAM-1/TGF β 2 mediated pathway. <i>PLoS ONE</i> , 2018, 13, e0200079.	2.5	24
41	Increased CD4+ T cell lineage commitment determined by CpG methylation correlates with better prognosis in urinary bladder cancer patients. <i>Clinical Epigenetics</i> , 2018, 10, 102.	4.1	24
42	Tissue-resident memory T cells are epigenetically cytotoxic with signs of exhaustion in human urinary bladder cancer. <i>Clinical and Experimental Immunology</i> , 2018, 194, 39-53.	2.6	48
43	Neoadjuvant Chemotherapy Reinforces Antitumour T cell Response in Urothelial Urinary Bladder Cancer. <i>European Urology</i> , 2018, 74, 688-692.	1.9	28
44	Doxorubicin enhances the capacity of B cells to activate T cells in urothelial urinary bladder cancer. <i>Clinical Immunology</i> , 2017, 176, 63-70.	3.2	24
45	Evaluation of the diagnostic accuracy of UBC [®] Rapid in bladder cancer: a Swedish multicentre study. <i>Scandinavian Journal of Urology</i> , 2017, 51, 293-300.	1.0	17
46	Molecular Subgroup of Primary Prostate Cancer Presenting with Metastatic Biology. <i>European Urology</i> , 2017, 72, 509-518.	1.9	26
47	Cohort profile: The Swedish National Register of Urinary Bladder Cancer (SNRUBC) and the Bladder Cancer Data Base Sweden (BladderBaSe). <i>BMJ Open</i> , 2017, 7, e016606.	1.9	44
48	Sentinel node detection in muscle-invasive urothelial bladder cancer is feasible after neoadjuvant chemotherapy in all pT stages, a prospective multicenter report. <i>World Journal of Urology</i> , 2017, 35, 921-927.	2.2	14
49	Swedish National Penile Cancer Register: incidence, tumour characteristics, management and survival. <i>BJU International</i> , 2016, 117, 287-292.	2.5	76
50	Detection of micrometastases by flow cytometry in sentinel lymph nodes from patients with renal tumours. <i>British Journal of Cancer</i> , 2016, 115, 957-966.	6.4	23
51	A retrospective evaluation of preoperative anemia in patients undergoing radical cystectomy for muscle-invasive urothelial urinary bladder cancer, with or without neoadjuvant chemotherapy. <i>SpringerPlus</i> , 2016, 5, 1167.	1.2	9
52	B cells in tumor draining lymph nodes act as efficient antigen presenting cells in cancer patients. , 2015, 3, .		0
53	Pilot study of adoptive immunotherapy with sentinel node-derived T cells in muscle-invasive urinary bladder cancer. <i>Scandinavian Journal of Urology</i> , 2015, 49, 453-462.	1.0	13
54	EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2013 Guidelines. <i>European Urology</i> , 2014, 65, 778-792.	1.9	868

#	ARTICLE	IF	CITATIONS
55	The Impact of the Extent of Lymphadenectomy on Oncologic Outcomes in Patients Undergoing Radical Cystectomy for Bladder Cancer: A Systematic Review. <i>European Urology</i> , 2014, 66, 1065-1077.	1.9	164
56	Vascular endothelial growth factor receptor 2, but not S100A4 or S100A6, correlates with prolonged survival in advanced urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1215-1224.	1.6	9
57	Multiplex B Cell Characterization in Blood, Lymph Nodes, and Tumors from Patients with Malignancies. <i>Journal of Immunology</i> , 2013, 190, 5847-5855.	0.8	53
58	The effects of chemotherapeutic drugs on human monocyte-derived dendritic cell differentiation and antigen presentation. <i>Clinical and Experimental Immunology</i> , 2013, 172, 490-499.	2.6	57
59	The many flavors of tumor-associated B cells. <i>OncImmunology</i> , 2013, 2, e25237.	4.6	4
60	Response to Comment on "Multiplex B Cell Characterization in Blood, Lymph Nodes, and Tumors from Patients with Malignancies". <i>Journal of Immunology</i> , 2013, 191, 4471.2-4472.	0.8	1
61	Pathologic Downstaging Is a Surrogate Marker for Efficacy and Increased Survival Following Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Urothelial Bladder Cancer. <i>European Urology</i> , 2012, 61, 1229-1238.	1.9	230
62	Sentinel node detection in renal cell carcinoma. A feasibility study for detection of tumour-draining lymph nodes. <i>BJU International</i> , 2012, 109, 1134-1139.	2.5	29
63	FOXP3 and survival in urinary bladder cancer. <i>BJU International</i> , 2011, 108, 1672-1678.	2.5	139
64	Treatment of Muscle-invasive and Metastatic Bladder Cancer: Update of the EAU Guidelines. <i>European Urology</i> , 2011, 59, 1009-1018.	1.9	570
65	Editorial Comment on: FDG-PET/CT for the Preoperative Lymph Node Staging of Invasive Bladder Cancer. <i>European Urology</i> , 2010, 57, 647.	1.9	2
66	Feasibility of T-Cell-Based Adoptive Immunotherapy in the First 12 Patients with Advanced Urothelial Urinary Bladder Cancer. Preliminary Data on a New Immunologic Treatment Based on the Sentinel Node Concept. <i>European Urology</i> , 2010, 58, 105-111.	1.9	27
67	Current Status of Prognostic Immunohistochemical Markers for Urothelial Bladder Cancer. <i>Tumor Biology</i> , 2008, 29, 311-322.	1.8	25
68	Treatment of muscle-invasive bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 1279-1283.	2.4	24
69	Re: Phase II trial of neoadjuvant gemcitabine and cisplatin in patients with resectable bladder carcinoma. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2007, 33, 840-841.	1.5	0
70	Detection of Immune Responses Against Urinary Bladder Cancer in Sentinel Lymph Nodes. <i>European Urology</i> , 2006, 49, 59-70.	1.9	39
71	Hybrid SPECT-CT: An Additional Technique for Sentinel Node Detection of Patients with Invasive Bladder Cancer. <i>European Urology</i> , 2006, 50, 83-91.	1.9	79
72	Neoadjuvant Cisplatin Based Combination Chemotherapy in Patients with Invasive Bladder Cancer: A Combined Analysis of Two Nordic Studies. <i>European Urology</i> , 2004, 45, 297-303.	1.9	220

#	ARTICLE	IF	CITATIONS
73	RE: EXTENDED RADICAL LYMPHADENECTOMY IN PATIENTS WITH UROTHELIAL BLADDER CANCER: RESULTS OF A PROSPECTIVE MULTICENTER STUDY. <i>Journal of Urology</i> , 2004, 172, 386-386.	0.4	2
74	Early Metastatic Progression of Bladder Carcinoma: Molecular Profile of Primary Tumor and Sentinel Lymph Node. <i>Journal of Urology</i> , 2002, 168, 2240-2244.	0.4	26
75	Endovascular Approach to Treating Secondary Arteriooureteral Fistula. <i>Scandinavian Journal of Urology and Nephrology</i> , 2002, 36, 80-82.	1.4	21
76	Neoadjuvant Cisplatin-Methotrexate Chemotherapy for Invasive Bladder Cancer - Nordic Cystectomy Trial 2. <i>Scandinavian Journal of Urology and Nephrology</i> , 2002, 36, 419-425.	1.4	164
77	Early metastatic progression of bladder carcinoma: molecular profile of primary tumor and sentinel lymph node. <i>Journal of Urology</i> , 2002, 168, 2240-4.	0.4	8
78	LYMPHATIC MAPPING AND DETECTION OF SENTINEL NODES IN PATIENTS WITH BLADDER CANCER. <i>Journal of Urology</i> , 2001, 166, 812-815.	0.4	97
79	Lymphatic mapping and detection of sentinel nodes in patients with bladder cancer. <i>Journal of Urology</i> , 2001, 166, 812-5.	0.4	21
80	Thromboembolic events during neoadjuvant chemotherapy in muscle invasive bladder cancer – any correlation to the central venous access? A clinical practice article. <i>F1000Research</i> , 0, 11, 40.	1.6	1